Drug
Quemliclustat clinical trials
Also written AB680.
- studies test it
- 11
- open now
- 4
- in phase 3
- 1
- first study started
- 2018
Keep track of what changes. Save the quemliclustat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- AB680
- 11
Studies by the year they started
11 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 7
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 5
Arcus Biosciences, Inc. (5) · Nataliya Uboha (1) · Gilead Sciences (1) · Fred Hutchinson Cancer Center (1) · Jonsson Comprehensive Cancer Center (1) · Gulam Manji (1) · Catherine Spina (1)
Often tested with
Tested in the same studies.
Zimberelimab (3) · Domvanalimab (2) · AB928 (2) · Fluorouracil (1) · Leucovorin (1) · Oxaliplatin (1) · Gemcitabine (1) · Cisplatin (1)
Studies
Open first, then newest update. How each study uses quemliclustat is read from its arms, and is right about nine times in ten.
Testing it · 11
- Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial CancerRecruitingPhase 1/2Fred Hutchinson Cancer CenterNCT07667335Written as Quemliclustat
- Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic AdenocarcinomaRecruitingPhase 1/2Jonsson Comprehensive Cancer CenterNCT05688215Written as Quemliclustat
- Combination Therapy in Patients With Localized Pancreatic Ductal AdenocarcinomaRecruitingPhase 2Gulam ManjiNCT06048484Written as Quemliclustat
- Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate CancerRecruitingPhase 2Catherine SpinaNCT05915442Written as Quemliclustat
- Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal AdenocarcinomaActive, not recruitingPhase 3Arcus Biosciences, Inc.NCT06608927Written as Quemliclustat
- A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract MalignanciesActive, not recruitingPhase 2Arcus Biosciences, Inc.NCT05329766Written as Quemliclustat
- Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)Active, not recruitingPhase 2Nataliya UbohaNCT06048133Written as Quemliclustat
- Study With Various Immunotherapy Treatments in Participants With Lung CancerActive, not recruitingPhase 2Gilead SciencesNCT05676931Written as Quemliclustat
- Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)CompletedPhase 1Arcus Biosciences, Inc.NCT07364214Written as Quemliclustat
- A Study to Investigate the Safety of AB680 in Healthy VolunteersCompletedPhase 1Arcus Biosciences, Inc.NCT03677973Written as AB680
- A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy VolunteersCompletedPhase 1Arcus Biosciences, Inc.NCT04575311Written as AB680
Given in every arm · 3 — quemliclustat is usual care beside what is tested
- A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal MalignanciesCompletedPhase 1Arcus Biosciences, Inc.NCT04104672Written as AB680
- An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.CompletedPhase 1/2Arcus Biosciences, Inc.NCT04660812Written as AB680
- Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate CancerCompletedPhase 1/2Arcus Biosciences, Inc.NCT04381832Written as Quemliclustat
Codes
What other systems call quemliclustat · ClinicalTrials.gg INT001984
- MeSH (NLM) C000723779quemliclustatConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) J6K8WSV73AQUEMLICLUSTATConfirmed FDA, NLM
- NCI Thesaurus C167156QuemliclustatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000723779 | quemliclustat | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | J6K8WSV73A | QUEMLICLUSTAT | Confirmed FDA, NLM |
| NCI Thesaurus | C167156 | Quemliclustat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.